A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period.

Conditions

Polymyalgia Rheumatica
Inflammatory Diseases

Interventions

DRUG: AIN457
DRUG: ACZ885
DRUG: Prednisone
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals